Loading
Yanuki
KEYWORD TOPIC
Sanofi and Regeneron's Itepekimab Shows Mixed Results in COPD Trials | Sanofi and Regeneron's Itepekimab Shows Mixed Results in COPD Trials

Pharma / Clinical Trials

Sanofi and Regeneron's Itepekimab Shows Mixed Results in COPD Trials

Sanofi and Regeneron's investigational drug, itepekimab, designed for chronic obstructive pulmonary disease (COPD), has yielded mixed outcomes in its Phase 3 clinical trials. While one study (AERIFY-1) achieved its primary endpoint, a paral...

Next-gen COPD drug from Sanofi, Regeneron shows mixed results in Phase 3 trials
Sanofi and Regeneron's Itepekimab Shows Mixed Results in COPD Trials Image via STAT
TOPIC regn stock